(Health Times reporter Gao Ruirui) Since March, a large number of new drugs have been included in the accepted varieties one after another. The Health Times reporter combed the relevant information of the State Drug Administration and found that as of March 29, there were a total of 75 drugs. The new drug is included in the catalogue of varieties accepted by the State Food and Drug Administration, involving Hengrui Medicine, Qilu Pharmaceutical, Nuocheng Jianhua and other pharmaceutical companies.
According to the information on the official website of the State Drug Administration, there are 55 new drugs involving registration category 1, which are SAP-001 tablets of Shanghai Shenton Pharmaceutical Technology Co., Ltd.; Jiangsu Hengrui SHR4640 Tablets of Pharmaceutical Co., Ltd.; FCN-159 Tablets of Shanghai Fosun Pharmaceutical Industry Development Co., Ltd.; BGB-11417 Film-Coated Tablets of BeiGene (Suzhou) Biotechnology Co., Ltd.; BGB of BeiGene (Suzhou) Biotechnology Co., Ltd. -11417 film-coated tablets; QLH11906 tablets of Qilu Pharmaceutical Co., Ltd.; polysaccharide superparamagnetic iron oxide injection and other new drugs from Chia Tai Tianqing Pharmaceutical Group Co., Ltd.; Beijing Nuocheng Jianhua Pharmaceutical Technology Co., Ltd. and Wuxi Orbrutinib tablets from Hequan Pharmaceutical Co., Ltd.
Public information shows that SHR4640 is a class 1.1 URAT1 selective inhibitor independently developed by Hengrui Medicine, which is mainly used for the treatment of gout and hyperuricemia. Uric acid-lowering effect and safety.
InnoCare official website information shows that on December 25, 2020, orelabrutinib was approved in China for relapsed/refractory chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia Two indications for patients with cell lymphoma (SLL), and patients with relapsed/refractory mantle cell lymphoma (MCL). In addition, orelabrutinib is also actively expanding its other indications in the field of oncology and autoimmunity, including marginal zone lymphoma (MZL), central system lymphoma (CNSL), Waldenström macroglobulinemia (WM), diffuse large B-cell lymphoma (DLBCL) and multiple sclerosis.
According to the 2021 performance report released by Nuocheng Jianhua, the annual revenue has risen sharply from 1.4 million yuan in 2020 to 1.043 billion yuan in 2021, mainly due to orelabrutinib sales revenue and Bojian’s down payment. Nuocheng Jianhua’s only currently marketed BTK inhibitor, orbrutinib, has achieved total sales of 241 million yuan since its commercialization in January 2021. At present, the product has covered more than 1,000 hospitals in more than 260 cities, and will be included in the new medical insurance catalogue in December 2021.
